|
1
|
Esteva FJ, Baranau YV, Baryash V, Manikhas
A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy
D, Pikiel J, et al: Efficacy and safety of CT-P6 vs. reference
trastuzumab in HER2-positive early breast cancer: Updated results
of a randomised phase 3 trial. Cancer Chemother Pharmacol.
84:839–847. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rugo HS, Barve A, Waller CF,
Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M,
Kothekar M, Loganathan S, et al: Effect of a proposed trastuzumab
biosimilar compared with trastuzumab on overall response rate in
patients with ERBB2 (HER2)-positive metastatic breast cancer: A
randomized clinical trial. JAMA. 317:37–47. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pegram MD, Bondarenko I, Zorzetto MMC,
Hingmire S, Iwase H, Krivorotko PV, Lee KS, Li RK, Pikiel J,
Aggarwal R, et al: PF-05280014 (a trastuzumab biosimilar) plus
paclitaxel compared with reference trastuzumab plus paclitaxel for
HER2-positive metastatic breast cancer: A randomised, double-blind
study. Br J Cancer. 120:172–182. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Esteva FJ, Stebbing J, Wood-Horrall RN,
Winkle PJ, Lee SY and Lee SJ: A randomised trial comparing the
pharmacokinetics and safety of the biosimilar CT-P6 with reference
trastuzumab. Cancer Chemother Pharmacol. 81:505–514.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sato K and Kohgo Y: Infusion reactions.
Gan To Kagaku Ryoho. 35:1671–1674. 2008.PubMed/NCBI(In Japanese).
|
|
6
|
Suter TM, Procter M, van Veldhuisen DJ,
Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin
C, Klijn JG, et al: Trastuzumab-associated cardiac adverse effects
in the herceptin adjuvant trial. J Clin Oncol. 25:3859–3865.
2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sengupta PP, Northfelt DW, Gentile F,
Zamorano JL and Khandheria BK: Trastuzumab-induced cardiotoxicity:
Heart failure at the crossroads. Mayo Clin Proc. 83:197–203.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Kolberg HC, Colleoni M, Demetriou GS,
Santi P, Tesch H, Fujiwara Y, Tomasevic Z and Hanes V: Cardiac
safety of the trastuzumab biosimilar ABP 980 in Women with
HER2-positive early breast cancer in the randomized, double-blind,
active-controlled LILAC Study. Drug Saf. 43:233–242.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Smith I, Procter M, Gelber RD, Guillaume
S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G,
Baselga J, et al: 2-year follow-up of trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer: A randomised
controlled trial. Lancet. 369:29–36. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li RK, Tokunaga E, Adamchuk H, Vladimirov
V, Yanez E, Lee KS, Bondarenko I, Vana A, Hilton F, Ishikawa T, et
al: Long-Term Safety and effectiveness of PF-05280014 (a
Trastuzumab Biosimilar) Treatment in patients with HER2-Positive
metastatic breast cancer: Updated results of a randomized,
double-blind study. BioDrugs. 36:55–69. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Stebbing J, Baranau Y, Baryash V, Manikhas
A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii
D, Pikiel J, et al: CT-P6 compared with reference trastuzumab for
HER2-positive breast cancer: A randomised, double-blind,
active-controlled, phase 3 equivalence trial. Lancet Oncol.
18:917–928. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tatsuta R, Sumimoto T, Nakahara R, Tanaka
R and Itoh H: Comparison of treatment safety between brand-name
product and biosimilar of trastuzumab. Gan To Kagaku Ryoho.
48:945–949. 2021.PubMed/NCBI(In Japanese).
|
|
14
|
Thompson LM, Eckmann K, Boster BL, Hess
KR, Michaud LB, Esteva FJ, Hortobágyi GN and Barnett CM: Incidence,
risk factors, and management of infusion-related reactions in
breast cancer patients receiving trastuzumab. Oncologist.
19:228–234. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chan AS, Freeswick S and Sklarin NT:
Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30
minutes. Cancer Res. 69 (2 suppl)(S3150)2009.
|
|
16
|
Ring A, Simcock R, Mitra S, Bloomfield D,
King J, Simpson S, Sadler G and Webb A: Infusion of trastuzumab
maintenance doses over 30 minutes. Ann Oncol. 19:1509–1510.
2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tsutsui H, Isobe M, Ito H, Ito H, Okumura
K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, et al: JCS
2017/JHFS 2017 guideline on diagnosis and treatment of acute and
chronic heart failure-Digest Version. Circ J. 83:2084–2184.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Guarneri V, Lenihan DJ, Valero V, Durand
JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi
GN and Esteva FJ: Long-term cardiac tolerability of trastuzumab in
metastatic breast cancer: The M.D. Anderson Cancer Center
experience. J Clin Oncol. 24:4107–4115. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Čelutkienė J, Pudil R, López-Fernández T,
Grapsa J, Nihoyannopoulos P, Bergler-Klein J, Cohen-Solal A,
Farmakis D, Tocchetti CG, von Haehling S, et al: Role of
cardiovascular imaging in cancer patients receiving cardiotoxic
therapies: A position statement on behalf of the Heart Failure
Association (HFA), the European Association of Cardiovascular
Imaging (EACVI) and the Cardio-Oncology Council of the European
Society of Cardiology (ESC). Eur J Heart Fail. 22:1504–1524.
2020.PubMed/NCBI View Article : Google Scholar
|
